View Item 

Show simple item record

Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry

dc.contributor.authorAbtan, Jérémie
dc.contributor.authorBhatt, Deepak L.
dc.contributor.authorElbez, Yedid
dc.contributor.authorSorbets, Emmanuel
dc.contributor.authorEagle, Kim
dc.contributor.authorIkeda, Yasuo
dc.contributor.authorWu, David
dc.contributor.authorHanson, Mary E.
dc.contributor.authorHannachi, Hakima
dc.contributor.authorSinghal, Puneet K.
dc.contributor.authorSteg, Philippe Gabriel
dc.contributor.authorDucrocq, Gregory
dc.date.accessioned2017-01-10T19:05:55Z
dc.date.available2018-01-08T19:47:53Zen
dc.date.issued2016-11
dc.identifier.citationAbtan, Jérémie ; Bhatt, Deepak L.; Elbez, Yedid; Sorbets, Emmanuel; Eagle, Kim; Ikeda, Yasuo; Wu, David; Hanson, Mary E.; Hannachi, Hakima; Singhal, Puneet K.; Steg, Philippe Gabriel; Ducrocq, Gregory (2016). "Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry." Clinical Cardiology 39(11): 670-677.
dc.identifier.issn0160-9289
dc.identifier.issn1932-8737
dc.identifier.urihttps://hdl.handle.net/2027.42/135334
dc.publisherWiley Periodicals, Inc.
dc.subject.otherischemic risk
dc.subject.othermyocardial infarction
dc.subject.otherIschemic heart disease
dc.subject.othervorapaxar
dc.titleResidual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialities
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135334/1/clc22583.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135334/2/clc22583-sup-0001-AppendixS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135334/3/clc22583_am.pdf
dc.identifier.doi10.1002/clc.22583
dc.identifier.sourceClinical Cardiology
dc.identifier.citedreferenceSteg PG, Bhatt DL, Wilson PW, et al; REACH Registry Investigators. One‐year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197 – 1206.
dc.identifier.citedreferenceBonaca MP, Bhatt DL, Cohen M, et al; PEGASUS‐TIMI 54 Steering Committee and Investigators. Long‐term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791 – 1800.
dc.identifier.citedreferenceBhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706 – 1717.
dc.identifier.citedreferenceUdell JA, Bonaca MP, Collet JP, et al. Long‐term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta‐analysis of randomized trials. Eur Heart J. 2016; 37: 390 – 399.
dc.identifier.citedreferenceScirica BM, Bonaca MP, Braunwald E, et al; TRA 2°P‐TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P‐TIMI 50 trial. Lancet. 2012; 380: 1317 – 1324.
dc.identifier.citedreferenceMorrow DA, Braunwald E, Bonaca MP, et al; TRA 2°P‐TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404 – 1413.
dc.identifier.citedreferenceDucrocq G, Bhatt DL, Labreuche J, et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. Eur J Prev Cardiol. 2014; 21: 1509 – 1516.
dc.identifier.citedreferenceD’Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286: 180 – 187.
dc.identifier.citedreferenceAvezum A, Makdisse M, Spencer F, et al; GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2005; 149: 67 – 73.
dc.identifier.citedreferenceDepta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost. 2010; 104: 657 – 663.
dc.identifier.citedreferenceRuff CT, Bhatt DL, Steg PG, et al; REACH Registry Investigators. Long‐term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014; 170: 413 – 418.
dc.identifier.citedreferenceNieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow‐up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008; 29: 1181 – 1189.
dc.identifier.citedreferenceSmith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association [published correction appears in J Am Coll Cardiol. 2015;65:1495]. J Am Coll Cardiol. 2011; 58: 2432 – 2446.
dc.identifier.citedreferenceTang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long‐term mortality post acute coronary syndrome [published correction appears in Am Heart J. 2007;154:851]. Am Heart J. 2007; 153: 29 – 35.
dc.identifier.citedreferenceJhund PS, Macintyre K, Simpson CR, et al. Long‐term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009; 119: 515 – 523.
dc.identifier.citedreferenceHaeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. Stroke. 2011; 42: 2977 – 2982.
dc.identifier.citedreferenceBhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180 – 189.
dc.identifier.citedreferenceBhatt DL, Peterson ED, Harrington RA, et al; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009; 30: 1195 – 1202.
dc.identifier.citedreferenceKearney PM, Blackwell L, Collins R, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy of cholesterol‐lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta‐analysis. Lancet. 2008; 371: 117 – 125.
dc.identifier.citedreferenceBaigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‐analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670 – 1681.
dc.identifier.citedreferenceCannon CP, Blazing MA, Giugliano RP, et al; IMPROVE‐IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387 – 2397.
dc.identifier.citedreferenceSabatine MS, Giugliano RP, Wiviott SD, et al; OSLER Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500 – 1509.
dc.identifier.citedreferenceRobinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1489 – 1499.
dc.identifier.citedreferenceDesai NR, Sabatine MS. PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc Med. 2015; 25: 567 – 574.
dc.identifier.citedreferenceSabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk trial. Am Heart J. 2016; 173: 94 – 101.
dc.identifier.citedreferenceSchwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long‐term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168: 682 – 689.
dc.identifier.citedreferenceStone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in J Am Coll Cardiol. 2014;63(25 part B):3024–3025 and J Am Coll Cardiol. 2015;66:2812]. J Am Coll Cardiol. 2014; 63 ( 25 part B ): 2889 – 2934.
dc.identifier.citedreferenceDucrocq G, Wallace JS, Baron G, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010; 31: 1257 – 1265.
dc.identifier.citedreferenceMega JL, Braunwald E, Wiviott SD, et al; ATLAS‐ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9 – 19.
dc.identifier.citedreferencePuymirat E, Simon T, Steg PG, et al; FAST‐MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST‐elevation myocardial infarction. JAMA. 2012; 308: 998 – 1006.
dc.identifier.citedreferenceWallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045 – 1057.
dc.identifier.citedreferenceWiviott SD, Braunwald E, McCabe CH, et al; TRITON‐TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001 – 2015.
dc.identifier.citedreferenceCannon CP, Braunwald E, McCabe CH, et al; PROVE IT–TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [ published correction appears in N Engl J Med. 2006;354:778 ]. N Engl J Med. 2004; 350: 1495 – 1504.
dc.identifier.citedreferencePuymirat E, Schiele F, Steg PG, et al; FAST‐MI Investigators. Determinants of improved one‐year survival in non–ST‐segment elevation myocardial infarction patients: insights from the French FAST‐MI program over 15 years. Int J Cardiol. 2014; 177: 281 – 286.
dc.identifier.citedreferenceFox KA, Carruthers K, Steg PG, et al; GRACE Investigators. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. Eur Heart J. 2010; 31: 667 – 675.
dc.identifier.citedreferenceSteg PG, López‐Sendón J, Lopez DS, et al; GRACE Investigators. External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007; 167: 68 – 73.
dc.identifier.citedreferenceBhatt DL, Eagle KA, Ohman EM, et al; REACH Registry Investigators. Comparative determinants of 4‐year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350 – 1357.
dc.identifier.citedreferenceDucrocq G, Amarenco P, Labreuche J, et al. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation. 2013; 127: 730 – 738.
dc.identifier.citedreferenceOhman EM, Bhatt DL, Steg PG, et al; REACH Registry Investigators. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events‐study design. Am Heart J. 2006; 151: 786.e1 – 786.e10.
dc.identifier.citedreferenceWilson PW, D’Agostino R Sr, Bhatt DL, et al; REACH Registry Investigators. An international model to predict recurrent cardiovascular disease. Am J Med. 2012; 125: 695.e1 – 703.e1.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
clc22583.pdf
Size:
1.044MB
Format:
PDF
View/Open
Name:
clc22583-sup-0001-AppendixS1.pdf
Size:
640.9KB
Format:
PDF
View/Open
Name:
clc22583_am.pdf
Size:
870.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.